Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation
Launched by UNIVERSITY HOSPITAL, LIMOGES · Mar 6, 2017
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subject's written informed consent of the study
- • 2. Male and female (\>= 18 years)
- • 3. Recipients of a first kidney allograft
- • 4. Patients transplanted for less than 7 days at enrolment
- • 5. Patients affiliated to a social security system
- Exclusion Criteria:
- • 1. Patients presenting any contraindication to tacrolimus according to the summary of product characteristics of Adoport®
- • 2. Patient presenting anti-HLA antibodies against the graft in pre-transplantation (DSA)
- • 3. Recipients of any transplanted organ other than the kidney
- • 4. Pregnant (positive BHCG test) or lactating women
- • 5. Women without any method of contraception, except for women with no childbearing potential (according to the guidelines of the working group, Clinical Trial Facilitation Group, related to contraception and pregnancy test in clinical trials)
- • 6. Patients participating in any other interventional clinical study at inclusion as well as during the whole course of the current study
- • 7. Patient under judicial protection
- • 8. Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent, or who are unwilling to comply with the study protocol
About University Hospital, Limoges
The University Hospital of Limoges is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates patient care with cutting-edge research initiatives, fostering collaboration among healthcare professionals, researchers, and academic partners. With a commitment to improving patient outcomes and contributing to medical knowledge, the University Hospital of Limoges plays a pivotal role in translating scientific discoveries into effective therapeutic strategies. Its state-of-the-art facilities and expertise in various medical fields ensure rigorous trial management and adherence to ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Limoges, , France
Poitiers, , France
Rouen, , France
Tours, , France
Amiens, , France
Patients applied
Trial Officials
Pierre Marquet, MD
Principal Investigator
University Hospital, Limoges
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials